Mostrando 5 resultados de: 5
Filtros aplicados
Subtipo de publicación
Article(5)
Diagnostic value of alpha-fetoprotein for hepatocellular carcinoma
ArticleAbstract: Hepatocellular carcinoma (HCC) variously occupies the fifth or sixth position as the most frequent nPalabras claves:Alpha-fetoprotein, Cirrhosis, Hepatocelular carcinomaAutores:Cruz Y., Fernández I., Hernández J.C., I. Howland-Álvarez, Ivón Howland-Álvarez, Roque A., Samada M.Fuentes:googlescopusGrowth Hormone Releasing Peptide 6 (GHRP6) reduces liver fibrosis in CCl4 chronically intoxicated rats
ArticleAbstract: Tissue fibrosis is a leading cause of morbidity and mortality. Current treatments for conditions sucPalabras claves:Carbon tetrachloride, Cirrhosis, Cytoprotection, FIBROSIS, GHRP6, Liver, SecretagogueAutores:Abreu A., Berlanga-Acosta J., Bringas R., Cibrín D., Cintado A., Coro-Antich R., Cosme-Díz K., Cruz Y., Fernández-Massó J.R., García-del Barco D., González-Ferrer Y., Guillén I., Guillén-Nieto G.E., I. Howland-Álvarez, Inés L., Ivón Howland-Álvarez, León-Fernández O.S., López-Mola E., Mendoza-Marí Y., Miranda J., Nazabal M., Ochagavía M.E., Palenzuela D., Suaréz J., Ugarte-Moreno D., Vázquez-Blomquist D., Vila J.M.Fuentes:googlescopusOptimizing CIGB-300 intralesional delivery in locally advanced cervical cancer
ArticleAbstract: Background:We conducted a phase 1 trial in patients with locally advanced cervical cancer by injectiPalabras claves:B23/nucleophosmin, Cervical Cancer, CIGB-300, tumour uptakeAutores:Acevedo B.E., Alonso D.F., Ancízar J.A., Baladron I., Casacó C.A., Coca M.A., García I., Gómez R., González L.J., González Y.M., Hernández I., I. Howland-Álvarez, López-Saura P.A., Martínez Y.M., Molina L., Perea-Rodríguez S.E., Perera A., Perera Y., Prats A., Reyes V., Solares M., Torres L.A., Valenzuela-Silva C.M.Fuentes:scopusPharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteers
ArticleAbstract: Background: More potent antitumor activity is desired in Interferon (IFN)-treated cancer patients. TPalabras claves:2'-5' oligoadenylate synthetase, Beta2-microglobulin, interferons, Neopterin, pharmacodynamics, pharmacokineticsAutores:Bello-Rivero I., Campos-Mojena R., Cruz-Ramírez A., Díaz-Machado A., García-Vega Y., González-Delgado C.A., Hernández-González I., I. Howland-Álvarez, López-Saura P.A., Martín-Trujillo A., Pérez-Rodríguez S., Santana-Milián H., Tuero-Iglesias Á.D., Valenzuela-Silva C.M.Fuentes:scopusPreclinical safety demonstration of the human recombinant erythropoietin HEBERITRO®
ArticleAbstract: Erythropoietin (EPO) is a glycoprotein that appears in blood as a response to hypoxia, acting on bonPalabras claves:EPREX®, erythropoietin, Preclinical toxicology, safetyAutores:Bacardí D.M., Cosme K., Gutiérrez A., I. Howland-Álvarez, Ivón Howland-Álvarez, Merino N., Pérez-Caballero M., Porras D.N., Suaréz J., Urquiza D., Vázquez A.Fuentes:googlescopus